Search Results - "ПРОТИВОГРИБКОВЫЕ ПРЕПАРАТЫ"

1

Academic Journal

Clinical case of effective treatment of invasive mycosis caused by polyresistant strain of Candida auris ; Клинический случай успешного лечения инвазивного микоза, вызванного полирезистентным штаммом Candida auris

Authors: L. V. Selivanova, M. A. Balalaeva, O. V. Dymova, E. V. Chernova, M. V. Lukina, A. A. Krucenko, D. A. Petrenko, S. S. Dmitrieva, A. A. Eremenko, Л. В. Селиванова, М. А. Балалаева, О. В. Дымова, Е. В. Чернова, М. В. Лукина, А. А. Круценко, Д. А. Петренко, С. С. Дмитриева, А. А. Ерёменко

Source: Messenger of ANESTHESIOLOGY AND RESUSCITATION; Том 21, № 4 (2024); 85-91 ; Вестник анестезиологии и реаниматологии; Том 21, № 4 (2024); 85-91 ; 2541-8653 ; 2078-5658

Subject Terms: противогрибковые препараты, Candida auris, mycosis, candidemia, antifungal drugs, микоз, кандидемия

File Description: application/pdf

Relation: https://www.vair-journal.com/jour/article/view/1039/739; Иванов А. А., Куличенко Т. В. Candida auris: проблемы диагностики и лечения // Вопросы современной педиатрии. – 2020. – Т. 19, № 1. – С. 20–25. DOI:10.15690/vsp.v19i1.2081.; Кольцов И. П., Стрельникова Н. В., Витько Е. В. и др. Микробиологические свойства условно-патогенных сахаромицетов рода Candida при хронических, рецидивирующих инфекционно-воспалительных процессах (обзор литературы) // Тихоокеанский медицинский журнал. – 2023. – Т. 1. – С. 19–26. DOI:10.34215/1609-1175-2023-1-19-26.; Программа СКАТ (Стратегия Контроля Антимикробной Терапии) при оказании стационарной медицинской помощи: Российские клинические рекомендации / под ред. С. В. Яковлева, Н. И. Брико, С. В. Сидоренко, Д. Н. Проценко. – М.: Изд-во «Перо», 2018. – 156 с.; Chen J., Tian S., Han X. et al. Is the superbug fungus really so scary? A systematic review and meta-analysis of global epidemiology and mortality of Candida auris // BMC Infect Dis. – 2020. – Vol. 20, № 1. – P. 827. DOI:10.1186/s12879-020-05543-0.; Cleveland A.A., Farley M.M., Harrison L.H. et al. Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011 // Clin Infect Dis. – 2012. – Vol. 55, № 10. – P. 1352. DOI:10.1093/cid/cis697.; Cleveland A.A., Harrison L.H., Farley M.M. et al. Declining incidence of candidemia and the shifting epidemiology of Candida resistance in two US metropolitan areas, 2008–2013: results from population-based surveillance // PLoS One. – 2015. – Vol. 10, № 3. – P. e0120452. DOI:10.1371/journal.pone.0120452.; Dadar M., Tiwari R., Karthik K. et al. Candida albicans - Biology, molecular characterization, pathogenicity, and advances in diagnosis and control – An update // Microb Pathog. – 2018. – Vol. 117. – P. 128. DOI:10.1016/j.micpath.2018.02.028.; Fakhim H., Chowdhary A., Prakash A. et al. In Vitro Interactions of Echinocandins with Triazoles against Multidrug-Resistant Candida auris // Antimicrob Agents Chemother. – 2017. – Vol. 61, № 11. – P.e01056–17. DOI:10.1128/AAC.01056-17.; Fortún J., Meije Y., Buitrago M. J. et al. Clinical validation of a multiplex real-time PCR assay for detection of invasive candidiasis in intensive care unit patients // J AntimicrobChemother. – 2014. – Vol. 69, № 11. – P. 3134. DOI:10.1093/jac/dku225.; Hachem R., Hanna H., Kontoyiannis D. et al. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy // Cancer. – 2008. – Vol. 112, № 11. – P. 2493. DOI:10.1002/cncr.23466.; Hesstvedt L., Gaustad P., Andersen C. T. et al. Twenty-two years of candidaemia surveillance: results from a Norwegian national study // Clin Microbiol Infect. – 2015. – Vol. 21, № 10. – P. 938. DOI:10.1016/j.cmi.2015.06.008; Lamoth F., Lockhart S. R., Berkow E. L. et al. Changes in the epidemiological landscape of invasive candidiasis // J Antimicrob Chemother. – 2018. – Vol. 73, № 1. – P. i4. DOI:10.1093/jac/dkx444.; Larkin E., Hager C., Chandra J. et al. The emerging pathogen candida auris: growth phenotype, virulence factors, activity of antifungals, and effect of SCY-078, a novel glucan synthesis inhibitor, on growth morphology and biofilm formation // Antimicrob Agents Chemother. – 2017. – Vol. 61, № 5. – P. e02396. DOI:10.1128/AAC.02396-16.; Lockhart S. R., Etienne K. A., Vallabhaneni S. et al. simultaneous emergence of multidrug-resistant candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses // Clin Infect Dis. – 2017. – Vol. 64, № 2. – P. 134. DOI:10.1093/cid/ciw691.; Lockhart S. R., Messer S. A., Gherna M. et al. Identification of Candida nivariensis and Candida bracarensis in a large global collection of Candida glabrata isolates: comparison to the literature // J Clin Microbiol. – 2009. – Vol. 47, № 4. – P. 1216. DOI:10.1128/JCM.02315-08.; Quindós G. Epidemiology of candidaemia and invasive candidiasis. A changing face // Rev Iberoam Micol. – 2014. – Vol. 31, № 1. – P. 42. DOI:10.1016/j. riam.2013.10.001.; Quindós G. Marcos-Arias C., San-Millán R. et al. The continuous changes in the aetiology and epidemiology of invasive candidiasis: from familiar Candida albicans to multiresistant Candida auris // IntMicrobiol. – 2018. – Vol. 21, № 3. – P. 107. DOI:10.1007/s10123-018-0014-1.; Ruiz-Gaitán A., Moret A. M., Tasias-Pitarch M. et al. An outbreak due to Candida auris with prolonged colonisation and candidaemia in a tertiary care European hospital // Mycoses. – 2018. – Vol. 61, № 7. – P. 498. DOI:10.1111/myc.12781.; Satoh K., Makimura K., Hasumi Y. et al. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital // Microbiol Immunol. – 2009. – Vol. 53, № 1. – P. 41. DOI:10.1111/j.1348-0421.2008.00083.x.; Treviño-Rangel R. J., González G. M., Montoya A. M. et al. Recent Antifungal Pipeline Developments against Candida auris: A Systematic Review // J Fungi (Basel). – 2022. – Vol. 8, № 11. – P. 1144. DOI:10.3390/jof8111144.; Vinayagamoorthy K., Pentapati K. C., Prakash H. Prevalence, risk factors, treatment and outcome of multidrug resistance Candida auris infections in Coronavirus disease (COVID-19) patients: A systematic review // Mycoses. – 2022. – Vol. 65, № 6. – P. 613. DOI:10.1111/myc.13447.; https://www.cdc.gov/fungal/candida-auris/index.html

Availability: https://www.vair-journal.com/jour/article/view/1039
https://doi.org/10.24884/2078-5658-2024-21-4-85-91

View record from BASE

2

Academic Journal

Sinergistic effect on yeast of a mixture of microbial surfactants and antifungal drugs

Authors: Kliuchkа, I. V.

Subject Terms: antimicrobial properties, sinergistic effect, поверхностно-активные вещества, флуконазол, microbial surfactants, ПАВ, микробные ПАВ, синергическое действие, clotrimazole, противогрибковые препараты, fluconazole, antifungal drugs, антимикробная активность, клотримазол

File Description: application/pdf

Access URL: https://elib.belstu.by/handle/123456789/45209

3

Academic Journal

Development of curative and preventive antiseptic markers technology. Application in mycosis and skin damage complex therapy

Authors: Tykhonov, O. I., Frolova, O. E., Yarnykh, T. G., Shpychak, O. S., Martyniuk, T. V.

Source: Управління, економіка та забезпечення якості в фармації; № 4(56) (2018); 22-30
Upravlìnnâ, ekonomìka ta zabezpečennâ âkostì v farmacìï; № 4(56) (2018); 22-30
Управление, экономика и обеспечение качества в фармации; № 4(56) (2018); 22-30

Subject Terms: UDC: 616.992 : 615.282 : 615.453.8 : 615.014.2, УДК: 616.992 : 615.282 : 615.453.8 : 615.014.2, mycosis, anti-fungal medicines, vials-pencil (markers), technology, микозы, противогрибковые препараты, флаконы-карандаши (маркеры), технология, мікози, протигрибкові препарати, флакони-олівці (маркери), технологія, 3. Good health

File Description: application/pdf

Access URL: http://uekj.nuph.edu.ua/article/download/uekj.18.29/150031
http://uekj.nuph.edu.ua/article/download/uekj.18.29/150031
http://uekj.nuph.edu.ua/article/view/uekj.18.29
http://uekj.nuph.edu.ua/article/view/uekj.18.29

View record at OpenAIRE

4

Academic Journal

Features of antifungal therapy during long-lasting infectious process: a clinical case of fungal keratitis and profile of antifungal sensitivity based on assessing biofilm formation ; Особенности антифунгальной терапии при длительном инфекционном процессе: клинический случай грибкового кератита и анализ профиля противогрибковой чувствительности с учетом формирования биопленок

Authors: Valieva R.I., Lisovskaya S.A., Mayanskaya K.A., Samigullin D.V., Isaeva G.S.

Contributors: This work was supported by Grant No. 20 04 00247 of the Russian Foundation for Basic Research. Part of the work with the use of confocal microscopy was carried out within the framework of research on the state order of the Federal Research Center “Kazan Scientific Center of the Russian Academy of Sciences” (state registration No. ААААА181180227900839)., Работа выполнена при финансовой поддержке гранта РФФИ № 20 04 00247. Часть работы с применением конфокальной микроскопии проводилась в рамках исследований по госзаданию ФИЦ КазНЦ РАН (№ госрегистрации АААА А18 118022790083 9).

Source: Russian Journal of Infection and Immunity; Vol 11, No 4 (2021); 789-797 ; Инфекция и иммунитет; Vol 11, No 4 (2021); 789-797 ; 2313-7398 ; 2220-7619

Subject Terms: Fusarium, fungal keratitis, infectious process, antifungal agents, biofilm, confocal laser scanning microscopy, propidium iodide, acridine orange, грибы Fusarium, грибковый кератит, инфекционный процесс, противогрибковые препараты, биопленка, конфокальная лазерная сканирующая микроскопия, пропидий йодид, акридин оранжевый

File Description: application/pdf

Availability: https://iimmun.ru/iimm/article/view/1495
https://doi.org/10.15789/2220-7619-FOA-1495

View record from BASE

5

Academic Journal

Analysis of Сandida species distribution isolated from women with vulvovaginal candidiasis and their antifungal susceptibility profile

Authors: Burduniuc, O.S., Bîrcă, E.I., Burduniuc, A.M., Bivol, M.V., Iacon, O.S.

Source: Health of Society; Vol. 9 No. 6 (2020); 225-229
Здоровье общества-Zdorov'a suspil'stva; Том 9 № 6 (2020); 225-229
Здоров'я суспільства-Zdorov'a suspil'stva; Том 9 № 6 (2020); 225-229

Subject Terms: Candida non-albicans, Candida albicans, ВВК, противогрибковые препараты, Candida non-albicans, Candida albicans, VVC, antifungal agents, Candida non-albicans, Candida albicans, ВВК, протигрибкові препарати, 3. Good health

File Description: application/pdf

Access URL: http://health-society.zaslavsky.com.ua/article/view/226952

View record at OpenAIRE

6

Academic Journal

Candida auris: Problems in Diagnostics and Management ; Candida auris: проблемы диагностики и лечения

Authors: Artem A. Ivanov, Tatiana V. Kulichenko, А. А. Иванов, Т. В. Куличенко

Contributors: Not specified., Не указан.

Source: Current Pediatrics; Том 19, № 1 (2020); 20-25 ; Вопросы современной педиатрии; Том 19, № 1 (2020); 20-25 ; 1682-5535 ; 1682-5527

Subject Terms: эпидемиология, fungal infection, drug resistance, multi-drug resistance, multi-drug resistance microorganism, antimycotic medications, infection prevention, epidemiology, грибковая инфекция, лекарственная устойчивость, мультирезистентность, мультирезистентный микроорганизм, противогрибковые препараты, профилактика инфекций

File Description: application/pdf

Relation: https://vsp.spr-journal.ru/jour/article/view/2302/925; Global Action Fund for Fungal Infections [Internet], Global Action Fund for Fungal Infection. Improving outcomes for patients with fungal infections across the world: a roadmap for the next decade [cited 2017 April 5]. Available from: http://gaffi.org/wp-content/uploads/GAFFI_Road_Map_interactive-final0415.pdf.; Tudela JL, Denning DW. Recovery from serious fungal infections should be realisable for everyone. Lancet Infect Dis. 2017;17(11):1111-1113. doi:10.1016/S1473-3099(17)30319-5.; Brown GD, Denning DW, Gow NA, et al. Hidden killers: human fungal infections. Sci Transl Med. 2012;4(156):165rv13. doi:10.1126/scitranslmed.3004404.; Pappas PG, Lionakis MS, Arendrup MC, et al. Invasive candidiasis. Nat Rev Dis Primers. 2018;4:18026. doi:10.1038/nrdp.2018.26.; Pfaller MA. Epidemiology of nosocomial candidiasis: the importance of molecular typing. Braz J Infect Dis. 2000;4:161-167.; Satoh K, Makimura K, Hasumi Y et al. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol Immunol. 2009;53(1):41-44. doi:10.1111/j.1348-0421.2008.00083.; Kim MN, Shin JH, Sung H, et al. Candida haemulonii and closely related species at 5 university hospitals in Korea: identification, antifungal susceptibility, and clinical features. Clin Infect Dis. 2009;48(6):e57-e61. doi:10.1086/597108.; Lee WG, Shin JH, Uh Y, et al. First three reported cases of nosocomial fungemia caused by Candida auris. J Clin Microbiol. 2011;49(9):3139-3142. doi:10.1128/JCM.00319-11.; Cortegiani A, Misseri G, Fasciana T, et al. Epidemiology, clinical characteristics, resistance, and treatment of infections by Candida auris. J Intensive Care. 2018;6(69). doi:10.1186/s40560-018-0342-4.; Jeffery-Smith A, Taori SK, Schelenz S, et al. Candida auris: a review of the literature. Clin Microbiol Rev. 2017;31(1):e00029-17. doi:10.1128/CMR.00029-17.; Lockhart SR, Etienne KA, Vallabhaneni S, et al. Simultaneous emergence of multidrug-resistant Candida auris on 3 continents Confirmed by whole-genome sequencing and epidemiological analyses. Clin Infect Dis. 2017;64(2):134-140. doi:10.1093/cid/ciw691.; Ruiz-Gaitan A, Moret AM, Tasias-Pitarch M, et al. An outbreak due to Candida auris with prolonged colonization and candidaemia in a tertiary care European hospital. Mycoses. 2018;61:498-505. doi:10.1111/myc.12781.; Kwon YJ, Shin JH, Byun SA, et al. Candida auris clinical isolates from south Korea: identification, antifungal susceptibility, and genotyping. J Clin Microbiol. 2019;57(4):e01624-18. doi:10.1128/JCM.01624-18.; Kean R, Ramage G. Combined antifungal resistance and biofilm tolerance: the global threat of Candida auris. mSphere. 2019;4(4):e00458-19. doi:10.1128/mSphere.00458-19.; Centers for Disease Control and Prevention [Internet], Antibiotic Resistance Threat Report [cited 2019 Novemder 13]. Available from: https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf.; Munoz JF, Gade L, Chow NA, et al. Genomic insights into multidrug-resistance, mating and virulence in Candida auris and related emerging species. Nat Commun. 2018;9(1):5346. doi:10.1038/s41467-018-07779-6.; Ben-Ami R, Berman J, Novikov A, et al. Multidrug-Resistant, Candida haemulonii and C. auris, Tel Aviv, Israel. Emerg Infect Dis. 2017;23:195-203. doi:10.3201/eid2302.161486.; Rudramurthy SM, Chakrabarti A, Paul RA, et al. Candida auris candidaemia in Indian ICUs: analysis of risk factors. J Antimicrob Chemother. 2017;72(6):1794-1801. doi:10.1093/jac/dkx034.; Sarma S, Upadhyay S. Current perspective on emergence, diagnosis and drug resistance in Candida auris. Infect Drug Resist. 2017;10:155-165. doi:10.2147/IDR.S116229.; Osei Sekyere J. Candida auris: a systematic review and metaanalysis of current updates on an emerging multidrug-resistant pathogen [published correction appears in Microbiologyopen. 2019;8(8):e00901]. Microbiologyopen. 2018;7(4):e00578. doi:10.1002/mbo3.578.; Vasilyeva N, Kruglov A, Pchelin I, et al. The first Russian case of candidaemia due to Candida auris. 28th European Conference of Clinical Microbiology and Infectious Diseases (ECCMID), Madrid, Spain 21-24 April 2018.; Kohlenberg A, Struelens MJ, Monnet DL, et al.; The Candida Auris Survey Collaborative Group. Candida auris: epidemiological situation, laboratory capacity and preparedness in European Union and European Economic Area countries, 2013 to 2017. Euro Surveill. 2018;23(13):18-00136. doi:10.2807/1560-7917.ES.2018.23.13.18-00136.; Centers for Disease Control and Prevention [Internet], CDC report of Tracking Candida auris [cited 2019 December 11]. Available from: https://www.cdc.gov/fungal/diseases/candidiasis/tracking-c-auris.html.; Chowdhary A, Voss A, Meis JF. Multidrug-resistant Candida auris: ‘new kid on the block' in hospital-associated infections. J Hosp Infect. 2016;94(3):209-212. doi:10.1016/j.jhin.2016.08.004.; De Cassia Orlandi Sardi J, Silva DR, Soares Mendes-Giannini MJ, et al. Candida auris: epidemiology, risk factors, virulence, resistance, and therapeutic options. Microb Pathog. 2018;125:116-121. doi:10.1016/j.micpath.2018.09.014.; Schelenz S, Hagen F, Rhodes JL, et al. First hospital outbreak of the globally emerging Candida auris in a European hospital. Antimicrob Resist Infect Control. 2016;5(35). doi:10.1186/s13756-016-0132-5.; Welsh RM, Bentz ML, Shams A, et al. Survival, persistence, and isolation of the emerging multidrug-resistant pathogenic yeast Candida auris on a plastic health care surface. J Clin Microbiol. 2017;55(10):2996-3005. doi:10.1128/JCM.00921-17.; Vallabhaneni S, Kallen A, Tsay S, et al. Investigation of the first seven reported cases of Candida auris, a globally emerging invasive, multidrug-resistant fungus — United States, May 2013 — August 2016. MMWR Morb Mortal Wkly Rep. 2016;65(44): 1234-1237. doi:10.15585/mmwr.mm6544e1.; Sarma S, Kumar N, Sharma S, et al. Candidemia caused by amphotericin B and fluconazole resistant Candida auris. Indian J Med Microbiol. 2013;31(1):90-91. doi:10.4103/0255-0857.108746.; Borman AM, Szekely A, Johnson EM. Comparative pathogenicity of United Kingdom isolates of the emerging pathogen Candida auris and other key pathogenic Candida species. mSphere. 2016;1(4):e00189-16. doi:10.1128/mSphere.00189-16.; Kumar D, Banerjee T, Pratap CB, Tilak R. Itraconazole-resistant Candida auris with phospholipase, proteinase and hemolysin activity from a case of vulvovaginitis. J Infect Dev Ctries. 2015;9: 435-437. doi:10.3855/jidc.4582.; Larkin E, Hager C, Chandra J, et al. The emerging pathogen Candida auris: growth phenotype, virulence factors, activity of anti-fungals, and effect of SCY-078, a novel glucan synthesis inhibitor, on growth morphology and biofilm formation. Antimicrob Agents Chemother. 2017;61(5):e02396-16. doi:10.1128/AAC.02396-16.; Sherry L, Ramage G, Kean R, et al. Biofilm-forming capability of highly virulent, multidrug-resistant Candida auris. Emerg Infect Dis. 2017;23(2):328-331. doi:10.3201/eid2302.161320.; Schwartz IS, Hammond GW. First reported case of multidrug-resistant Candida auris in Canada. Can Commun Dis Rep. 2017;43(7/8):150-153. doi:10.14745/ccdr.v43i78a02.; Centers for Disease Control and Prevention [Internet], Identification of Candida auris [cited 2019 October 16]. Available from: https://www.cdc.gov/fungal/candida-auris/recommendations.html.; Mizusawa M, Miller H, Green R, et al. Can multidrug-resistant Candida auris be reliably identified in clinical microbiology laboratories? J Clin Microbiol. 2017;55(2):638-640. doi:10.1128/JCM.02202-16.; Snayd M, Dias F, Ryan RW, et al. Misidentification of Candida auris by RapID yeast plus, a commercial, biochemical enzyme-based manual rapid identification system. J Clin Microbiol. 2018; 56(5):e00080-18. doi:10.1128/JCM.00080-18.; Kumar A, Sachu A, Mohan K, et al. Simple low cost differentiation of Candida auris from Candida haemulonii complex using CHROMagar Candida medium supplemented with Pal's medium. Revista Iberoamericana de Micologia. 2017;34(2):109-111. doi:10.1016/j.riam.2016.11.004.; Centers for Disease Control and Prevention [Internet], Algorithm to identify Candida auris based on phenotypic laboratory method and initial species identification [cited 2019 October 11]. Available from: https://www.cdc.gov/fungal/candida-auris/pdf/Testing-algorithm_by-Method_508.pdf.; Kordalewska M, Zhao Y, Lockhart SR, et al. Rapid and accurate molecular identification of the emerging multidrug-resistant pathogen Candida auris. J Clin Microbiol. 2017;55(8):2445-2452. doi:10.1128/JCM.00630-17.; Chowdhary A, Prakash A, Sharma C, et al. A multicentre study of antifungal susceptibility patterns among 350 Candida auris isolates (2009-2017) in India: role of the ERG11 and FKS1 genes in azole and echinocandin resistance. J Antimicrob Chemother. 2018;73(4):891-899. doi:10.1093/jac/dkx480.; Rybak JM, Doorley LA, Nishimoto AT, et al. Abrogation of triazole resistance upon deletion of CDR1 in a clinical isolate of Candida auris. Antimicrob Agents Chemother. 2019;63(4):e00057-19. doi:10.1128/AAC.00057-19.; Cowen LE, Sanglard D, Howard SJ, et al. Mechanisms of antifungal drug resistance. Cold Spring Harb Perspect Med. 2014;5(4):a019752. doi:10.1101/cshperspect.a019752.; Escandon P Chow NA, Caceres DH, et al. Molecular epidemiology of Candida auris in Colombia reveals a highly related, countrywide colonization with regional patterns in amphotericin B resistance. Clin Infect Dis. 2019;68(1):15-21. doi:10.1093/cid/ciy411.; Kordalewska M, Lee A, Park S, et al. Understanding echinocandin resistance in the emerging pathogen Candida auris. Antimicrob Agents Chemother. 2018;62(6):e00238-18. doi:10.1128/AAC.00238-18.; Fakhim H, Chowdhary A, Prakash A, et al. In vitro interactions of echinocandins with triazoles against multidrug-resistant Candida auris. Antimicrob Agents Chemother. 2017;61(11):e01056-17. doi:10.1128/AAC.01056-17.; Basso V, Garcia A, Tran DQ, et al. Fungicidal potency and mechanisms of 0-defensins against multidrug-resistant Candida species. Antimicrob Agents Chemother. 2018;62(6):e00111-18. doi:10.1128/AAC.00111-18.; Berkow EL, Angulo D, Lockhart SR. In vitro activity of a novel glucan synthase inhibitor, SCY-078, against clinical isolates of Candida auris. Antimicrob Agents Chemother. 2017;61(7):e00435-17. doi:10.1128/AAC.00435-17.; Berkow EL, Lockhart SR. Activity of CD101, a long-acting echinocandin, against clinical isolates of Candida auris. Diagn Microbiol Infect Dis. 2018;90(3):196-197. doi:10.1016/j.diagmicrobio.2017.10.021.; Zhao M, Lepak AJ, VanScoy B, et al. In vivo pharmacokinetics and pharmacodynamics of APX001 against Candida spp. in a neutropenic disseminated candidiasis mouse model. Antimicrob Agents Chemother. 2018;62(4):e02542-17. doi:10.1128/AAC.02542-17.; Centers for Disease Control and Prevention [Internet], Infection Prevention and Control for Candida auris [cited 2018 December 21]. Available from: https://www.cdc.gov/fungal/candida-auris/c-auris-infection-control.html.; Cadnum JL, Shaikh AA, Piedrahita CT, et al. Relative resistance of the emerging fungal pathogen Candida auris and other Candida species to killing by ultraviolet light. Infect Control Hosp Epidemiol. 2018;39(1):94-96. doi:10.1017/ice.2017.239.; Abdolrasouli A, Armstrong-James D, Ryan L, Schelenz S. In vitro efficacy of disinfectants utilised for skin decolonisation and en-vironmental decontamination during a hospital outbreak with Candida auris. Mycoses. 2017;60(11):758-763. doi:10.1111/myc.12699.

Availability: https://vsp.spr-journal.ru/jour/article/view/2302
https://doi.org/10.15690/vsp.v19i1.2081

View record from BASE

7

Academic Journal

Distribuția speciilor clinice de Candida și sensibilitatea acestora la antifungice

Authors: Burduniuc Popa, O.S., Bîrcă, E., Burduniuc, A., Grumeza, M.V., Bivol, M.A.

Source: Sănătate Publică, Economie şi Management în Medicină 87 (5) 32-37

Subject Terms: Candida non-albicans, Candida albicans, preparate antifungice, micoze, antifungal agents, mycoses, противогрибковые препараты, грибковые инфекции

File Description: application/pdf

Relation: info:eu-repo/grantAgreement/EC/FP7/17161/EU/Studierea rezistenței bacililor gramnegativi la antimicrobiene în vederea fortificării sistemului național de supravegherea și control al bolilor transmisibile/20.80009.8007.09; https://ibn.idsi.md/vizualizare_articol/114370; urn:issn:17298687

Availability: https://ibn.idsi.md/vizualizare_articol/114370

View record from BASE

8

Academic Journal

Geotrlchous stomatitis in the dental practice

Authors: L. V. Vdovina, N. V. Tiunova, S. M. Tolmacheva, I. N. Usmanova

Source: Эндодонтия Today, Vol 18, Iss 2, Pp 68-72 (2020)

Subject Terms: микоз, геотрихоз, кандидоз, вич-инфекция, онкогематологические заболевания, противогрибковые препараты, иммунодефицитные состояния, стоматит, грибковые заболевания, Dentistry, RK1-715

Relation: https://www.endodont.ru/jour/article/view/892; https://doaj.org/toc/1683-2981; https://doaj.org/toc/1726-7242; https://doaj.org/article/a7d8799411d444f7bd51854c09dc7d1b

Availability: https://doi.org/10.36377/1683-2981-2020-18-2-68-72
https://doaj.org/article/a7d8799411d444f7bd51854c09dc7d1b

View record from BASE

9

Academic Journal

Biologically oriented synthesis of medicines (BIODS) based on heterylpoxid 2,5- disubstituted 1,3,4-oxadiazoles (Part 1)

Authors: Karpenko, Yu. V., Panasenko, O. I., Knysh, Ye. H.

Source: Aktualʹnì Pitannâ Farmacevtičnoï ì Medičnoï Nauki ta Praktiki, Vol 13, Iss 2, Pp 302-314 (2020)
Current issues in pharmacy and medicine: science and practice; Vol. 13 No. 2 (2020)
Актуальные вопросы фармацевтической и медицинской науки и практики; Том 13 № 2 (2020)
Актуальні питання фармацевтичної та медичної науки та практики; Том 13 № 2 (2020)

Subject Terms: антибактериальная активность, antibacterial agents, протитуберкульозні агенти, 1 3 4-oxadiazoles, противоопухолевое действие, протипухлинна дія, anti-tuberculosis agents, антималярийные соединения, Pharmacy and materia medica, antitumor activity, antimalarial, 4-оксадіазоли, антималярійні сполуки, biods, протигрибкові препарати, антибактеріальна активність, противогрибковые препараты, 3. Good health, 4-oxadiazoles, RS1-441, 4-оксадиазол, antifungal agents, BIODS, противотуберкулезные агенты

File Description: application/pdf

Access URL: http://pharmed.zsmu.edu.ua/article/download/207211/207513
https://doaj.org/article/f3b248ce356e46bb858e22692ae94e98
http://pharmed.zsmu.edu.ua/article/download/207211/207513
http://pharmed.zsmu.edu.ua/article/view/207211
http://pharmed.zsmu.edu.ua/article/view/207211

View record at OpenAIRE Full Text Finder

10

Academic Journal

THE SENSITIVITY OF NATURAL YEAST ISOLATES TO A NUMBER OF ANTIFUNGAL AGENTS

Source: Естественные и технические науки.

Subject Terms: resistance, yeast isolates, изоляты дрожжей, чувствительность, устойчивость, antifungal agents, sensitivity, antimycotics, 3. Good health, противогрибковые препараты, антимикотики

11

Academic Journal

МАКРОРХАБДОЗ - ОППОРТУНИСТИЧЕСКАЯ ИНФЕКЦИЯ ПТИЦ: ДИАГНОСТИКА И ЛЕЧЕНИЕ

Subject Terms: декоративные и экзотические птицы, treatment, pathomorphological changes, макрорхабдоз, диагностика, лечение, 3. Good health, противогрибковые препараты, Macrorhabdus ornithogaster, macrorhabdosis, профилактика, prevention, патоморфологические изменения, diagnostics, antifungal drugs, decorative and exotic birds

12

Report

КРИПТОКОККОЗ. НОВЫЕ КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ (ОБЗОР)

Subject Terms: СПИД, криптококкоз легких, ВИЧ-инфекция, cryptococcosis, cryptococcal meningoencephalitis, флуконазол, Cryptococcus spp, криптококковый менингоэнцефалит, липосомальный амфотерицин В, HIV infection, lung cryptococcosis, 3. Good health, противогрибковые препараты, AIDS, fluconazole, Cryptococcus neoformans, криптококкоз, antifungal drugs, liposomal amphotericin B

13

Patent

Способ получения замещенных дигидробензофуранов

Subject Terms: органическая химия, противоопухолевые препараты, противовирусные препараты, лиганды, фармацевтическая промышленность, способ получения замещенных дигидробензофуранов, лечение заболеваний, биологически активные антагонисты, противогрибковые препараты

File Description: application/pdf

Access URL: https://elib.belstu.by/handle/123456789/59354

14

Patent

Способ получения 6-замещенных 2-метилбензофуранов

Subject Terms: органическая химия, противоопухолевые препараты, способ получения 6-замещенных 2-метилбензофуранов, противовирусные препараты, лиганды, фармацевтическая промышленность, лечение заболеваний, биологически активные антагонисты, противогрибковые препараты

File Description: application/pdf

Access URL: https://elib.belstu.by/handle/123456789/59277

15

Academic Journal

Генетическая регуляция формирования биопленки C. tropicalis

Authors: Черней, И.С., Чещевик, В.Т.

Subject Terms: биопленка C. tropicalis, дрожжевые грибы, гены, ответственные за образование биопленки, противогрибковые препараты

File Description: application/pdf

Relation: https://rep.polessu.by/handle/123456789/31182

Availability: https://rep.polessu.by/handle/123456789/31182

View record from BASE

16

Academic Journal

Комбінована дія евгенолу та протигрибкових препаратів на музейний штам С. аlbicans АТСС 102318 та клінічні штами С. аlbicans, виділених від хворих на зовнішній отит ; Комбинированное действие эвгенола и противогрибковых препаратов на музейный штамм С. аlbicans АТСС 102318 и клинические штаммы С. аlbicans, выделенных от больных наружным отитом ; The combinet effect of eugenol with antifungal drugs against museum stain of С. аlbicans АТСС 102318 and clinical isolates of С. аlbicans, isolated from panients with otitis externa.

Authors: Безшапочний, Сергій Борисович, Полянська, Валентина Павлівна, Зачепило, Світлана Вікторівна, Боброва, Нелля Олександрівна, Полянський, Валентин Олександрович, Безшапочный, Сергей Борисович, Полянская, Валентина Павловна, Зачепило, Светлана Викторовна, Боброва, Нелля Александровна, Полянский, Валентин Александрович, Bezshapochniy, S. B., Polyanska, V. P., Zachepylo, S. V., Bobrova, N. O., Polyanskii, V. O.

Subject Terms: эвгенол, протигрибкові препарати, клінічні штами С. аlbicans, противогрибковые препараты, клинические штаммы С. аlbicans, eugenol, clinical strains of С. Аlbicans, antifungal drugs

File Description: application/pdf

Relation: Комбінована дія евгенолу та протигрибкових препаратів на музейний штам С. аlbicans АТСС 102318 та клінічні штами С. аlbicans, виділених від хворих на зовнішній отит / С. Б. Безшапочний, В. П. Полянська, С. В. Зачепило [та ін.] // Журнал вушних, носових і горлових хвороб. – 2017. – № 3. – С. 62–68.; https://repository.pdmu.edu.ua/handle/123456789/2105

Availability: https://repository.pdmu.edu.ua/handle/123456789/2105

View record from BASE

17

Academic Journal